Bintrafusp Alfa News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PDS0101-Based Triplet Provides Survival Benefit in HPV16+ Cancers

The combination of PDS0101, PDS0301 (formerly M-9241), and bintrafusp alfa, an investigational immune checkpoint inhibitor extended survival in patients with advanced human papillomavirus 16–positive cancers, according to final data from a phase 2 trial (NCT04287868) led by the National Cancer Institute.

Frank beduBiotechnology corporationNational cancer instituteNational cancerBintrafusp alfaHuman papillomavirus positive cancersImmune checkpoint inhibitor

PRGN-2009 Plus Bintrafusp Alfa Shows Early Activity in HPV-Associated Malignancies

James L. Gulley, MD, PhD, reviews the safety and efficacy of PRGN-2009 alone and in combination with bintrafusp alfa in HPV-associated cancers and explains how this kind of approach may address an unmet clinical need.

United statesJamesl gulleyCancer researchNational cancer institutePrgn 2009Bintrafusp alfaHpv associated malignanciesAsco annual meeting

Merck to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021

Merck to Present Latest Highlights From Oncology Portfolio at WCLC and ESMO 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJulissa vianaEli lillyVertex pharmaceuticalsMerck pressEuropean commissionDrug administrationGlobal head of development for the healthcareEuropean medicines agencyEuropean society for medical oncologyWorld conferenceLung cancerEuropean societyMedical oncologyDanny bar zoharGlobal head

Data from Merck s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21

Data from Merck s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesJulissa vianaEli lillyInternational metastaticAmerican society of clinical oncologyNational cancer instituteMerck pressEuropean commissionDrug administrationMerck kgaGlobal head of development for the healthcareMerck kgaaData consortiumAmerican societyClinical oncologyAnnual meeting

PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results

PDS Biotech Provides Business Update and Reports First Quarter 2021 Financial Results Nachrichtenquelle: globenewswire | 13.05.2021, 13:00 | 43 | 0 FLORHAM PARK, N.J., May 13, 2021 (GLOBE NEWSWIRE) PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune T-cell activating technology, will discuss its financial results for the quarter ended March 31, 2021 and provide a business update on its conference call today. Recent Business Highlights: National Cancer Institute to present interim efficacy and safety data of PDS0101 Phase 2 clinical trial in an oral presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting on June 7, 2021. This trial is evaluating PDS0101 wit

United statesFrank beduDeanne randolphNational cancer instituteAmerican society of clinical oncologyDrug administrationBiotechnology corporation the companyUnited states securities exchangeMinistry of scienceAmerican societyClinical oncologyBintrafusp alfaScientific trainingFrank bedu addoChief executive officerVersamunet cell